Completed PHASE3 INTERVENTIONAL 2-arm NCT04607629

An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (NAP)

A Comparative Study of Efficacy and Safety of Genolar® and Xolar® in Treating Patients With Moderate to Severe Persistent Atopic Bronchial Asthma Inadequately Controlled With Stage 4 GINA (2017) Treatment

Sponsor: AO GENERIUM

Conditions Bronchial Asthma

Interventions Genolar® + Symbicort® Xolair® + Symbicort®

Updated 5 times since 2020 Last updated: Oct 23, 2020 Started: Jun 20, 2018 Primary completion: Apr 29, 2019 Completion: Dec 13, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bronchial Asthma, this trial is completed. The trial is conducted by AO GENERIUM and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AO GENERIUM

Data source: AO GENERIUM

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Barnaul, Russia , Kemerovo, Russia , Krasnodar, Russia , Moscow, Russia , Novosibirsk, Russia , Odintsovo, Russia , Omsk, Russia , Perm, Russia , Saint Petersburg, Russia and 6 more locations